CONDENSED INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015
Income Statement [Abstract]
Net revenues	$ 17,919	$ 6,543	$ 30,972	$ 11,751	$ 33,087
Cost of revenues	9,797	4,750	17,779	8,647	20,610
Impairment of field equipment	6,412		6,412
Gross profit	1,710	1,793	6,781	3,104	12,477
Operating costs and expenses:
Research, development and clinical trials	11,318	12,765	22,763	22,692	43,748
Sales and marketing	14,598	8,866	27,906	15,221	38,861
General and administrative	13,031	7,368	25,287	14,343	33,864
Total operating costs and expenses	38,947	28,999	75,956	52,256	116,473
Operating loss	(37,237)	(27,206)	(69,175)	(49,152)	(103,996)
Financial expenses, net	555	876	1,104	1,467	3,151
Loss before income tax expense	(37,792)	(28,082)	(70,279)	(50,619)	(107,147)
Income tax expense	2,820	1,275	5,770	2,011	4,434
Net loss	$ (40,612)	$ (29,357)	$ (76,049)	$ (52,630)	$ (111,581)
Basic and diluted net loss per ordinary share	$ (0.48)	$ (2.36)	$ (0.90)	$ (4.12)	$ (3.67)
Weighted average number of ordinary shares used in computing basic and diluted net loss per share	85,274,683	12,427,442	84,843,028	12,783,881	30,401,603